149 related articles for article (PubMed ID: 3016205)
1. Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.
Body JJ; Borkowski A; Cleeren A; Bijvoet OL
J Clin Oncol; 1986 Aug; 4(8):1177-83. PubMed ID: 3016205
[TBL] [Abstract][Full Text] [Related]
2. Treatment of tumor-induced osteolysis by APD.
Burckhardt P; Thiébaud D; Perey L; von Fliedner V
Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
[TBL] [Abstract][Full Text] [Related]
3. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE
Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
[TBL] [Abstract][Full Text] [Related]
4. Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia.
Body JJ; Pot M; Borkowski A; Sculier JP; Klastersky J
Am J Med; 1987 May; 82(5):957-63. PubMed ID: 3578365
[TBL] [Abstract][Full Text] [Related]
5. 3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer.
Coleman RE; Rubens RD
Br J Cancer; 1987 Oct; 56(4):465-9. PubMed ID: 3689664
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of aminohydroxypropylidene diphosphonate in the treatment of malignancy-associated hypercalcaemia.
Stevens MJ
Med J Aust; 1987 Mar; 146(5):261-4. PubMed ID: 3821622
[TBL] [Abstract][Full Text] [Related]
7. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy.
Morton AR; Cantrill JA; Craig AE; Howell A; Davies M; Anderson DC
Br Med J (Clin Res Ed); 1988 Mar; 296(6625):811-4. PubMed ID: 3130925
[TBL] [Abstract][Full Text] [Related]
8. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.
Ralston SH; Gardner MD; Dryburgh FJ; Jenkins AS; Cowan RA; Boyle IT
Lancet; 1985 Oct; 2(8461):907-10. PubMed ID: 2865417
[TBL] [Abstract][Full Text] [Related]
9. Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate.
Jacobs TP; Siris ES; Bilezikian JP; Baquiran DC; Shane E; Canfield RE
Ann Intern Med; 1981 Mar; 94(3):312-6. PubMed ID: 6452846
[TBL] [Abstract][Full Text] [Related]
10. Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions.
Body JJ; Magritte A; Seraj F; Sculier JP; Borkowski A
J Bone Miner Res; 1989 Dec; 4(6):923-8. PubMed ID: 2692407
[TBL] [Abstract][Full Text] [Related]
11. Effect of aminohydroxypropylidene diphosphonate on the bone metabolism of patients with parathyroid adenoma.
Ishimura E; Miki T; Koyama H; Harada K; Nakatsuka K; Inaba M; Nishizawa Y; Morii H
Horm Metab Res; 1993 Sep; 25(9):493-7. PubMed ID: 8225204
[TBL] [Abstract][Full Text] [Related]
12. A comparison of single and multiple intravenous infusions of 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD) in the treatment of hypercalcemia of malignancy.
Yates AJ; Murray RM; Jerums GJ; Martin TJ
Aust N Z J Med; 1987 Aug; 17(4):387-91. PubMed ID: 3435316
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.
Gucalp R; Ritch P; Wiernik PH; Sarma PR; Keller A; Richman SP; Tauer K; Neidhart J; Mallette LE; Siegel R
J Clin Oncol; 1992 Jan; 10(1):134-42. PubMed ID: 1727915
[TBL] [Abstract][Full Text] [Related]
14. Effects of amino-butylidene diphosphonate in hypercalcemia due to malignancy.
Bickerstaff DR; O'Doherty DP; McCloskey EV; Hamdy NA; Mian M; Kanis JA
Bone; 1991; 12(1):17-20. PubMed ID: 2054231
[TBL] [Abstract][Full Text] [Related]
15. Single high-dose (45 mg) infusions of aminohydroxypropylidene diphosphonate for severe malignant hypercalcemia.
Mannix KA; Carmichael J; Harris AL; Cantwell BM
Cancer; 1989 Sep; 64(6):1358-61. PubMed ID: 2766228
[TBL] [Abstract][Full Text] [Related]
16. Treatment of refractory cancer-associated hypercalcemia with aminohydroxypropylidene diphosphonate.
Heaf JG; Hansen M
Acta Med Scand; 1988; 224(3):287-8. PubMed ID: 3239457
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of hypercalcemia in osteolytic metastases with oral amino-hydroxypropylidene-diphosphonate].
Tubiana-Hulin M; de Vernejoul MC; Brière M; Miravet L; Clavel B
Presse Med; 1984 Feb; 13(8):483-6. PubMed ID: 6230630
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134
[TBL] [Abstract][Full Text] [Related]
19. Disodium pamidronate versus mithramycin in the management of tumour-associated hypercalcemia.
Ostenstad B; Andersen OK
Acta Oncol; 1992; 31(8):861-4. PubMed ID: 1290634
[TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.
Body JJ; Dumon JC; Gineyts E; Delmas PD
Br J Cancer; 1997; 75(3):408-12. PubMed ID: 9020487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
